Telomir Pharmaceuticals Inc TELO Q4 2025 Earnings WiderthanExpected Loss Highlights DevelopmentStage Challenges Biofrontera BFRI Q1 2026 Earnings EPS Misses Estimates by Wide Margin as Stock Rises IBRX Q1 2026 Earnings EPS Miss as Biotech Continues PreRevenue Advancement MGY Q1 2026 Earnings EPS Beats Expectations as Operational Efficiency Drives Surprise CBOE Q1 2026 Earnings EPS Surges Past Estimates with 1028 Beat Lisata Therapeutics Q3 2025 Earnings NarrowerthanExpected Loss as Biotech Advances Clinical Pipeline